Brii Biosciences Limited (BRIBF)
| Market Cap | 87.38M |
| Revenue (ttm) | 5.28M |
| Net Income (ttm) | -36.53M |
| Shares Out | n/a |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.126 |
| Previous Close | n/a |
| Day's Range | 0.126 - 0.126 |
| 52-Week Range | 0.125 - 0.445 |
| Beta | 1.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2024 |
About Brii Biosciences
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for th... [Read more]
Financial Performance
In 2023, Brii Biosciences's revenue was 56.32 million, a decrease of -53.94% compared to the previous year's 122.28 million. Losses were -174.83 million, -63.90% less than in 2022.
Financial numbers in CNY Financial StatementsNews
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy in...
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
DURHAM, N.C., and BEIJING , Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient he...
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic hum...
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine , PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated th...
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma ...
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING , M...
Brii Bio Publishes 2022 Environmental, Social and Governance Report
Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING , April 27, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a bi...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepatitis B viral ( HBV) infection and a potential first-of-its-kind treatment for postpartum depression...
Brii Biosciences Provides Update on Strategic Clinical Development Progress
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study plan...
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, suppor...
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has pote...
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING , Aug. 22, 2022 /PRNewswire/ --...
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to d...
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first local...
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING , July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii...
Brii Biosciences to be Added to MSCI China Small Cap Index
DURHAM, N.C. and BEIJING , May 24, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap In...
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant Review of the monoclonal antibody combination ...
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
DURHAM, N.C. and BEIJING , May 6, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for disease...
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAg obser ved in the Chinese patients infected with chronic hepatitis B DURHAM, N.C. and BEIJING, March 3...
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
DURHAM, N.C. and BEIJING, March 29, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseas...